NANOVIRICIDES, INC.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Kelly LoefflerSenate · R · GA |
NNVCNANOVIRICIDES, INC. · Stock |
Sale $1,001 - $15,000 |
May 1, 2020 | Apr 7, 2020 | Filing ↗ |
Whale Activity
- Increased9
- New10
- Held25
- Decreased5
- Closed7
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 919.3K | $1.2M | held |
| GEODE CAPITAL MANAGEMENT, LLC | 229.5K | $298K | increased |
| BlackRock, Inc. | 158.8K | $206K | held |
| Miller Financial Services LLC | 134.0K | $174K | increased |
| VANGUARD FIDUCIARY TRUST CO | 131.9K | $172K | held |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 126.3K | $164K | increased |
| RENAISSANCE TECHNOLOGIES LLC | 98.3K | $128K | decreased |
| Creative Planning | 86.8K | $113K | held |
| UBS Group AG | 70.4K | $92K | decreased |
| NORTHERN TRUST CORP | 64.2K | $83K | increased |
| STATE STREET CORP | 54.2K | $70K | held |
| Empowered Funds, LLC | 35.4K | $46K | new |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Diwan AnilPresident · Director | Gift | −94.5K | $0.00 | $0 | Aug 8, 2022 | Form 4 ↗ |
| BONIUK MILTON10% owner | Option exercise | +5.5M | — | — | May 21, 2018 | Form 4 ↗ |
| BONIUK MILTON10% owner | Grant / award | +120.7K | — | — | Jul 11, 2017 | Form 4 ↗ |
| BONIUK MILTON10% owner | Grant / award | +149.5K | — | — | May 4, 2017 | Form 4 ↗ |
| BONIUK MILTON10% owner | Grant / award | +153.6K | — | — | Feb 21, 2017 | Form 4 ↗ |
| BONIUK MILTON10% owner | Option exercise | +1.7M | — | — | Feb 21, 2017 | Form 4 ↗ |
| BONIUK MILTONDirector | Other | −605.5K | $0.00 | $0 | Feb 1, 2017 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +25.0K | $1.50 | $38K | May 19, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +25.0K | $1.50 | $38K | May 12, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +15.0K | $1.68 | $25K | May 4, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +2,900 | $1.68 | $5K | Apr 29, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +7,109 | $1.68 | $12K | Apr 28, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +25.0K | $1.78 | $45K | Apr 27, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +9,000 | $1.70 | $15K | Feb 18, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +141.8K | $1.18 | $167K | Feb 12, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +34.0K | $1.18 | $40K | Feb 12, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +34.0K | $1.18 | $40K | Feb 12, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +9,000 | $1.36 | $12K | Feb 10, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Grant / award | +9,000 | $1.40 | $13K | Feb 8, 2016 | Form 4 ↗ |
| BONIUK MILTONDirector | Purchase | +25.0K | $1.20 | $30K | Nov 11, 2015 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 653.5K | $902K | 0.00% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 245.3K | $339K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 124.6K | $156K | 0.00% | Aug 31, 2026 |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 36.0K | $50K | 0.03% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 35.3K | $44K | 0.00% | Aug 31, 2026 |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 23.7K | $30K | 0.00% | Aug 31, 2026 |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 20.5K | $28K | 0.00% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list NNVC's shares (CUSIP 630087302), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
No lobbying filings found naming NANOVIRICIDES, INC. as the client.
Government Contracts
No federal contract awards found for NANOVIRICIDES, INC..
U.S. Patents
No USPTO patent applications found for NANOVIRICIDES, INC..
Annual Financials
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Operating income | -$8.3M | -$9.6M | -$8.5M | -$8.9M | -$8.1M |
| Net income | -$8.2M | -$9.5M | -$8.3M | -$8.6M | -$8.1M |
| Diluted EPS | -$0.41 | -$0.63 | -$0.70 | -$0.74 | -$0.70 |
| Operating cash flow | -$7.7M | -$8.5M | -$6.3M | -$5.7M | -$5.9M |
| Cash and equivalents | $2.8M | $1.6M | $4.8M | $8.1M | $14.1M |
| Total assets | $9.9M | $8.8M | $12.8M | $16.9M | $23.5M |
| Total liabilities | $1.2M | $1.3M | $1.4M | $2.0M | $413K |
| Shareholders' equity | $8.7M | $7.5M | $11.5M | $14.9M | $23.1M |
As NANOVIRICIDES, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Sep 28, 2026 ↗
Stock Splits
- 1-for-20Reverse splitSep 24, 2019
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 5.02, 9.01Officer / director changeSep 29, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsJul 30, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementJul 17, 2026
EDGAR ↗ - 8-K · Items 7.01Reg FD disclosureMay 21, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsMay 20, 2026
EDGAR ↗
About NANOVIRICIDES, INC.
Organization and Nature of Business NanoViricides, Inc. (the “Company”, “NanoViricides”, “we,” or “us”) was incorporated in Nevada on April 1, 2005, and redomiciled to Delaware effective May 30, 2023. Our corporate offices are located at 1 Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137. Our Website is located at http://www.Nanoviricides.com. We do not incorporate by reference into this Annual Report the information on or accessible through our website, and you should not consider it part of this Annual Report. On September 25, 2013, the Company’s common stock began trading on the New York Stock Exchange American under the symbol, “NNVC”. We are a clinic…

